Clinical trial · Interventional
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
NCT05113342CI-TRIAL-00082456terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Phase 1 enrollment completed. Further clinical development terminated.
Summary
Brief summary (as posted)
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Relapse Multiple Myeloma | Plasma Cell Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Descartes-25 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Arm 1: Dose Level 1
- description
- Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
- interventionNames
- Drug: Descartes-25
- type
- EXPERIMENTAL
- label
- Arm 2: Dose Level 2
- description
- Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
- interventionNames
- Drug: Descartes-25
- type
- EXPERIMENTAL
- label
- Arm 3: Dose Level 3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years and older' * diagnosed with active R/RMM, who have failed 2 lines of treatment * have measurable disease Exclusion Criteria: \- Patients with active plasma cell leukemia
References
Publications (0)
Data not yet available
No reference posted for this study.